Literature DB >> 28650471

Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions.

J Zámborszky, B Szikriszt, J Z Gervai, O Pipek, Á Póti, M Krzystanek, D Ribli, J M Szalai-Gindl, I Csabai, Z Szallasi, C Swanton, A L Richardson, D Szüts.   

Abstract

This corrects the article DOI: 10.1038/onc.2016.243.

Entities:  

Year:  2017        PMID: 28650471      PMCID: PMC5582208          DOI: 10.1038/onc.2017.213

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


Correction to: Oncogene (2017) 36, 746–755; doi:10.1038/onc.2016.243; published online 25 July 2016 In Figure 2c, the label above the middle panel in this paper was published incorrectly. The correct label should read BRCA1−/− instead of BRCA2−/−. The corrected figure 2 is below.
Figure 2

Triplet mutation spectrum and genomic distribution of SNVs. Triplet mutation spectra of the mock treatment (a) or MMS treatment (b) of the indicated cell lines. Each mutation class, as indicated at the top of the panel, is separated into 16 categories based on the identity of the preceding and following nucleotide. The mutation rate at each triplet was obtained by dividing the number of observed mutations with the number of occurrences of that particular triplet in the chicken genome. The sequence of triplets is shown on expanded Supplementary figures S2-S5; the four C>T peaks in mock-treated samples represent NCG>NTG mutations. (c) In mock-treated clones of the indicated genotypes, the distance of each SNV mutation from the previous SNV on the same chromosome is plotted against the genomic position of the mutation. Thin vertical lines indicate chromosome boundaries. Chromosomes are shown in numerical order, chromosome Z is shown last on the right. The colour of each dot illustrates the type of mutation according to the key at the bottom of the panel. One sequenced clone of each cell line is shown.

Triplet mutation spectrum and genomic distribution of SNVs. Triplet mutation spectra of the mock treatment (a) or MMS treatment (b) of the indicated cell lines. Each mutation class, as indicated at the top of the panel, is separated into 16 categories based on the identity of the preceding and following nucleotide. The mutation rate at each triplet was obtained by dividing the number of observed mutations with the number of occurrences of that particular triplet in the chicken genome. The sequence of triplets is shown on expanded Supplementary figures S2-S5; the four C>T peaks in mock-treated samples represent NCG>NTG mutations. (c) In mock-treated clones of the indicated genotypes, the distance of each SNV mutation from the previous SNV on the same chromosome is plotted against the genomic position of the mutation. Thin vertical lines indicate chromosome boundaries. Chromosomes are shown in numerical order, chromosome Z is shown last on the right. The colour of each dot illustrates the type of mutation according to the key at the bottom of the panel. One sequenced clone of each cell line is shown. The publishers wish to apologise for any inconvenience caused.
  13 in total

Review 1.  Time for remodeling: SNF2-family DNA translocases in replication fork metabolism and human disease.

Authors:  Sarah A Joseph; Angelo Taglialatela; Giuseppe Leuzzi; Jen-Wei Huang; Raquel Cuella-Martin; Alberto Ciccia
Journal:  DNA Repair (Amst)       Date:  2020-08-15

2.  High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster.

Authors:  Sakshi Jasra; Orsi Giricz; Rachel Zeig-Owens; Kith Pradhan; David G Goldfarb; Angelica Barreto-Galvez; Alexander J Silver; Jiahao Chen; Srabani Sahu; Shanisha Gordon-Mitchell; Gaurav S Choudhary; Srinivas Aluri; Tushar D Bhagat; Aditi Shastri; Cosmin A Bejan; Shannon S Stockton; Travis P Spaulding; Victor Thiruthuvanathan; Hiroki Goto; Jeannine Gerhardt; Syed Hissam Haider; Arul Veerappan; Matthias Bartenstein; George Nwankwo; Ola Landgren; Michael D Weiden; Jacqueline Lekostaj; Ryan Bender; Frederick Fletcher; Lee Greenberger; Benjamin L Ebert; Ulrich Steidl; Britta Will; Anna Nolan; Advaitha Madireddy; Michael R Savona; David J Prezant; Amit Verma
Journal:  Nat Med       Date:  2022-03-07       Impact factor: 87.241

3.  Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut.

Authors:  O Pipek; D Ribli; J Molnár; Á Póti; M Krzystanek; A Bodor; G E Tusnády; Z Szallasi; I Csabai; D Szüts
Journal:  BMC Bioinformatics       Date:  2017-01-31       Impact factor: 3.169

Review 4.  Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy.

Authors:  Janusz Blasiak; Elzbieta Pawlowska; Jan Chojnacki; Joanna Szczepanska; Michal Fila; Cezary Chojnacki
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

5.  Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.

Authors:  M Diossy; L Reiniger; Z Sztupinszki; M Krzystanek; K M Timms; C Neff; C Solimeno; D Pruss; A C Eklund; E Tóth; O Kiss; O Rusz; G Cserni; T Zombori; B Székely; J Kulka; J Tímár; I Csabai; Z Szallasi
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

Review 6.  Mutational signatures: experimental design and analytical framework.

Authors:  Gene Koh; Xueqing Zou; Serena Nik-Zainal
Journal:  Genome Biol       Date:  2020-02-14       Impact factor: 13.583

Review 7.  Regulation of Error-Prone DNA Double-Strand Break Repair and Its Impact on Genome Evolution.

Authors:  Terrence Hanscom; Mitch McVey
Journal:  Cells       Date:  2020-07-09       Impact factor: 6.600

Review 8.  Decoding human cancer with whole genome sequencing: a review of PCAWG Project studies published in February 2020.

Authors:  Simona Giunta
Journal:  Cancer Metastasis Rev       Date:  2021-06-07       Impact factor: 9.264

9.  The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.

Authors:  Alexandra Gráf; Márton Zsolt Enyedi; Lajos Pintér; Éva Kriston-Pál; Gábor Jaksa; Árpád Bálind; Éva Ezer; Péter Horváth; Farkas Sükösd; Ernő Kiss; Lajos Haracska
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

10.  Mutations in BRCA2 and taxane resistance in prostate cancer.

Authors:  Cathleen Nientiedt; Martina Heller; Volker Endris; Anna-Lena Volckmar; Stefanie Zschäbitz; María A Tapia-Laliena; Anette Duensing; Dirk Jäger; Peter Schirmacher; Holger Sültmann; Albrecht Stenzinger; Markus Hohenfellner; Carsten Grüllich; Stefan Duensing
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.